Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Breast Cancer
Interventions
DRUG

Herceptin

Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.

DRUG

Sunitinib

SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.

DRUG

Taxotere

The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.

Trial Locations (7)

1000

Pfizer Investigational Site, Brussels

1200

Pfizer Investigational Site, Brussels

2610

Pfizer Investigational Site, Wilrijk

6000

Pfizer Investigational Site, Charleroi

9100

Pfizer Investigational Site, Sint-Niklaas

20132

Pfizer Investigational Site, Milan

47014

Pfizer Investigational Site, Meldola

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00372424 - Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive | Biotech Hunter | Biotech Hunter